TABLE 4.

Health Care Costs for Patients Newly Diagnosed with NVAF in OAC-Naive Dabigatran and Warfarin Cohorts After Propensity Score Matching

Post-index Costsa	Dabigatran Cohort (n = 824) Mean (SD) Median ($)	Warfarin Cohort (n = 824) Mean (SD) Median ($)	P Valueb (Comparing Means)
Total costsc	3,151 (±6,744) 1,270	3,221 (±6,869) 1,255	0.701
Pharmacy costs
Overall pharmacy	455 (±429) 355	328 (±517) 187	< 0.001
AF-related pharmacy	32 (±71) 0	20 (±55) 0	0.006
Other pharmacy	423 (±422) 326	308 (±515) 163	< 0.001
Medical costs
Overall medical	2,696 (±6,699) 809	2,893 (±6,819) 960	0.179
Hospitalizations
All-cause	1,481 (±6,189) 0	1,518 (±5,958) 0	0.994
Stroke-related	41 (±523) 0	117 (±2,091) 0	0.279
Myocardial infarction-related	157 (±3,678) 0	225 (±3,053) 0	0.428
Bleed-related	70 (±787) 0	132 (±2,119) 0	0.450
Emergency department visits
All-cause	71 (±277) 0	76 (±419) 0	0.549
Stroke-related	0 (±8) 0	3 (±94) 0	0.999
Myocardial infarction-related	1 (±23) 0	1 (±36) 0	0.565
Bleed-related	1 (±16) 0	2 (±23) 0	0.460
Physician office visits
All-cause	197 (±545) 125	232 (±351) 164	< 0.001
Stroke-related	3 (± 19) 0	2 (± 14) 0	0.476
Myocardial infarction-related	0 (±3) 0	1 (±9) 0	0.083
Bleed-related	0 (±1) 0	0 (±0) 0	0.564
Outpatient visits
All-cause	946 (±2,015) 320	1,067 (±2,350) 373	0.621
Stroke-related	11 (±155) 0	4 (±58) 0	0.158
Myocardial infarction-related	2 (±30) 0	1 (±24) 0	0.350
Bleed-related	3 (±47) 0	9 (±196) 0	0.121

^aHealth care costs were measured as PPPM.

^bWilcoxon signed rank sum test was used.

^cOverall medical costs plus overall pharmacy costs.

AF = atrial fibrillation; NVAF = nonvalvular atrial fibrillation; OAC = oral anticoagulant; PPPM = per patient per month; SD = standard deviation.